Literature DB >> 12774214

Deep brain stimulation for the treatment of Parkinson's disease: the experience of the Neurosurgical Department in Monza.

A Landi1, M Parolin, R Piolti, A Antonini, M Grimaldi, M Crespi, S Iurlaro, A Aliprandi, G Pezzoli, C Ferrarese, S M Gaini.   

Abstract

deep brain stimulation is a widely accepted surgical therapy for the symptomatic treatment of advanced parkinson's disease; high frequency chronic stimulation of the subthalamic nucleus proved its efficacy to control the major motor symptoms. In the neurosurgical department of Monza we treated 72 parkinsonian patients (November 1998-January 2003). One year follow-up results are: decrease of tremor 90%, hypertonous 56%, bradykinesia 70%, voice impairment amelioration 30%, mean total daily L-dopa intake reduced 58%. Freezing and balance did not ameliorate, some voice impairment and psychic derangement have been observed. Major surgical complications were: haemorrage (1 case - transient hemiparesis), infections (2 cases), pulmonary embolisation (1 case). To optimise the surgical results, careful clinical and instrumental selection of the patients are mandatory before surgery.

Entities:  

Mesh:

Year:  2003        PMID: 12774214     DOI: 10.1007/s100720300039

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

1.  Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson's disease.

Authors:  R R Goodman; B Kim; S McClelland; P B Senatus; L M Winfield; S L Pullman; Q Yu; B Ford; G M McKhann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 2.  Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches.

Authors:  Aparna Wagle Shukla; Michael Scott Okun
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Neuroimaging and deep brain stimulation.

Authors:  D Dormont; D Seidenwurm; D Galanaud; P Cornu; J Yelnik; E Bardinet
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-12       Impact factor: 4.966

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.